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Reduction in allergen-specific IgE binding as
measured by microarray: A possible surrogate
marker for effects of specific immunotherapy
To the Editor:
In vivo provocation test methods (eg, skin testing and
conjunctival provocation testing)1 are useful surrogates for
clinical improvement, but the identification of in vitro markers
for monitoring the effects of specific immunotherapy (SIT) has
been a long-sought goal. It has been shown that allergen-
specific blocking IgG antibodies inhibit allergen-induced mast
cell and basophil degranulation as well as IgE-facilitated allergen
presentation to T cells and is associated with a reduction of in vivo
sensitivity.1-4 Cellular assays (eg, basophil activation assays and
FAB assay)5,6 may allow uncovering and measuring the effects
of allergen-specific blocking antibodies on the allergen-IgE
interaction and to correlate in vitro results with clinical outcomes
but are quite cumbersome.
We recently found that measurements of allergen-specific IgE
levels performed in the presence of low allergen concentrations in
the solid phase, for example, allergen microarrays, allow
visualizing the inhibition of IgE binding in the presence of
blocking IgG antibodies when allergen-specific blocking IgG
antibodies are present.7 Therefore, it may be hypothesized that
IgE measurements performed using low allergen concentrations
such as in allergen microarrays may better reflect the in vivo
patients’ situation (ie, the patients’ sensitivity).
We aimed to study the influence of SIT-induced allergen-
specific IgG antibodies on IgE binding in microarray and CAP
assays and to determine whether IgE levels measured by
microarray are associated with clinical parameters. For
this purpose, residual serum samples from a double-blind
placebo-controlled immunotherapy trial performed in birch
pollen–allergic patients with recombinant hypoallergenic Bet v
1 derivatives were analyzed.2 Sera were obtained before and 2015 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma& Immunology. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).immediately after treatment, shortly after the following birch
season, and 1 year after starting the treatment (see timeline in
Fig E1 in this article’s Online Repository at www.jacionline.
org) (placebo group, n 5 27; recombinant Bet v 1 fragments,
n 5 17; recombinant Bet v 1 trimer, n 5 21). A demographic
characterization of the patients and their treatment (ie, cumulative
doses administered and numbers of injections) can be found in
Table E1 in this article’s Online Repository at www.jacionline.
org. Recombinant Bet v 1 fragments and trimer administered in
this study are described in this article’s Online Repository at
www.jacionline.org.
Sera (Fig E1) were analyzed for Bet v 1–specific IgE and IgG
levels by ImmunoCAP and ISAC, a multiallergen chip that
contained 103 allergen-specific components to record kinetics
of IgE and IgG responses (Thermo Fisher/Phadia AB, Uppsala,
Sweden). Linear contrasts after ANOVA and correlations were
calculated using Statistica 10.0 (StatSoft, Tulsa, Okla) and
SPSS 22.0 (IBM, Armonk, NY).
In those patients who received active treatment and thus
developed high levels of allergen-specific IgG, the detected
Bet v 1–specific IgE antibodies differed strongly between
ImmunoCAP and ISAC measurements in the sera obtained after
but not before treatment. ImmunoCAP measurements showed
significant increases in Bet v 1–specific IgE antibodies after
treatment/before pollen season in both actively treated groups
(Fig 1, A; see Table E2 in this article’s Online Repository at
www.jacionline.org), whereas detected Bet v 1–specific IgE
levels decreased significantly when measured by ISAC compared
to placebo-treated patients. Boosts of allergen-specific IgE
production caused by seasonal allergen exposure were found in
the ‘‘after-season’’ samples from all patients by ISAC and
ImmunoCAP measurements, but, as earlier reported, increases
were lower for actively treated patients than for placebo-treated
patients2 (Fig 1, B). The decrease in Bet v 1–specific IgE
measured by ISAC in the actively treated groups was associated
with a strong increase in Bet v 1–specific IgG found by both
CAP and ISAC measurements (Fig 1, C and D) and thus may
be explained by blocking of Bet v 1–specific IgE binding by
therapy-induced IgG in the ISAC. Immunization experiments
performed with rBet v 1 fragments and trimer in animals
following an immunization scheme close to the one used for
this study showed that the trimer is more immunogenic than the
fragments.8 This fits the observation that the trimer induced
higher Bet v 1–specific IgG levels after vaccination as determined
by quantitative CAP measurements (Fig 1, C, CAP: IgG increase
comparing before treatment with after treatment; P< .05) than the
fragments in the patients. Fragment-treated and trimer-treated
patients had received comparable cumulative doses of the
vaccines (Table E1). Therefore, the higher increase in Bet v
1–specific IgG in the trimer group was not due to different
cumulative doses injected.
In contrast to the ISAC measurements, an increase in Bet v
1–specific IgE was found by CAP measurements because
allergen is present in excess in the solid phase and therefore
SIT-induced Bet v 1–specific IgE becomes visible. In fact, it is
known that SIT also induces a rise in allergen-specific IgE.9 No
relevant alterations in Bet v 1–specific IgG antibodies were
observed for placebo-treated patients (Fig 1, C and D).
Rises in Bet v 1–specific IgE were observed for all groups
as a result of seasonal allergen exposure after the pollen
season and allergen-specific IgE then declined again 1 year
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FIG 1. Courses of geometric means and 95% CIs of Bet v 1–specific IgE (A: ImmunoCAP; B: ISAC) and IgG
(C: ImmunoCAP; D: ISAC) levels (y-axes) over the study period (x-axes) for placebo- (blue), fragment-
(green), and trimer-treated patients (orange). *P < .05 and **P < .01. Asterisks show the significance of
changes within particular groups from the time point before treatment to after treatment, from after treat-
ment to after season, and from after season to after 1 year. ISU, ISAC Standardized Unit.
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Similar results of IgE and IgG antibody reactivities to Bet v
1–related pollen and plant food allergens (rAln g 1: alder;
rCor a 1: hazel; rMal d 1: apple; rPru p 3: peach) were noted,
but responses were lower than for Bet v 1, mirroring the
degree of sequence similarity with Bet v 1 (Aln g 1 > Cor
a 1 > Mal d 1 > Pru p 3) (see Figs E2 and E3 in this arti-
cle’s Online Repository at www.jacionline.org).
Next, we compared alterations in nasal allergen sensitivity as
determined by active anterior rhinomanometry with changes in
allergen-specific IgE levels measured by ISAC for those patients
for whom nasal provocation data were available before treatment
and after the pollen season (placebo, n 5 22; rBet v 1 fragment,
n5 12; rBet v 1 trimer, n5 16) (Fig 2). Results obtained 1 year
after starting the treatment (Fig E1) were not analyzed because
IgG levels had declined almost to baseline at this time point
(Fig 1) and no differences between groups were found by nasal
provocation.10 Nasal provocation was performed using in-
creasing doses of natural birch pollen extract containing defined
Bet v 1 concentrations. Changes in nasal allergen tolerance in the
patients are represented by positive (increased nasal allergen
tolerance) or negative (decreased nasal allergen tolerance)
points, where 1 point indicates a 10-fold change to the results
measured before treatment (Fig 2, y-axes).10 When changes in
nasal sensitivity and allergen-specific IgE were plotted against
each other, it became visible that patients with increases in Bet
v 1–specific IgE without improvement or deterioration in nasalsensitivity were mainly found in the placebo group (Fig 2, pla-
cebo: right lower quarter) whereas patients with reduced Bet v
1–specific IgE were frequently observed in the actively treated
group and often tolerated higher allergen doses during nasal
provocation (Fig 2, left upper quarter; fragments: 25%, 3 of 12
patients, and trimer: 31.3%, 5 of 16 patients). Fig 2 shows
that there is a significant correlation of the reduction in Bet v
1–specific IgE binding measured by ISAC with increased nasal
allergen tolerance in the trimer-treated group (r 5 20.620;
P 5 .012). No significant correlation of the reduction in
IgE binding to Bet v 1 determined by ISAC was found
with increased nasal allergen tolerance in fragment-treated
patients, which may be explained by the lower induction
of allergen-specific IgG by fragments as compared to trimer
(Fig 1, C and D).
Considering all treatment groups, decreases in IgE measured
by ISAC seemed to be useful for the prediction of clinical
improvement because we found a clinical improvement
prediction of 90% (ie, 100% for placebo and trimer groups and
71% for the fragment group). This was not the case for increases
in DIgE as measured by the ISAC, which was associated with a
clinical worsening prediction of only 25% for the placebo group
and 20% for trimer and fragment groups, respectively.
A limitation of our study is that data were available only for a
relatively small number of patients but our results indicate that
decreases in allergen-specific IgE as measured on the chip are
associated with reduced nasal allergen sensitivities. This effect
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FIG 2. Association of alterations in Bet v 1–specific IgE levels determined by ISAC and nasal allergen
tolerance. Y-axes (positive range) indicate increased allergen-specific tolerance, wherein 1-point increase
indicates tolerance of a 10-fold higher allergen concentration and 1-point decrease indicates a 10-fold higher
sensitivity. X-axes indicate the log fold changes of Bet v 1–specific IgE when comparing prestudy levels
(ie, before treatment; see Fig 1 and Fig E1) to levels after the pollen season (ie, after season; see Fig 1
and Fig E1). ISU, ISAC Standardized Unit.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2015
808 LETTERS TO THE EDITORwas not at all observed when changes in allergen-specific
IgE were measured under conditions of allergen excess by
CAP because IgE levels increased in the placebo- and actively
treated patients (see Fig E4 in this article’s Online Repository at
www.jacionline.org).
The results of our study thus indicate that allergen microarrays
are useful to monitor the development of allergen-specific IgG
responses during SIT, both against the allergen present in the SIT
vaccine as well as against cross-reactive allergens. Moreover, the
reduction in allergen-specific IgE binding measured by micro-
array analysis may be a useful surrogate marker for clinical
effects of SIT, warranting more extensive prospective studies
designed to analyze the association of IgE levels measured by
microarray with results from in vivo allergen provocation and
clinical end points.
Eva Wollmann, MDa
Christian Lupinek, MDa
Michael Kundi, PhDb
Regina Selb, MScc
Verena Niederberger, MDc
Rudolf Valenta, MDa
From athe Division of Immunopathology, Department of Pathophysiology and Allergy
Research, Center for Pathophysiology, Infectiology and Immunology, bthe Institute
of Environmental Health, Center of Public Health, and cthe Department of Ear,
Nose and Throat Diseases, Medical University of Vienna, Vienna, Austria. E-mail:
rudolf.valenta@meduniwien.ac.at.This study was supported by the PhD program IAI DK W1212 and projects F4605 and
F4613 of the Austrian Science Fund (Fonds zur F€orderung der wissenschaftlichen
Forschung) as well as by a research grant from Thermo Fisher, Uppsala, Sweden.
Disclosure of potential conflict of interest: C. Lupinek has received lecture fees from
Thermo Fisher. M. Kundi has received consultancy fees from Baxter, Novartis, and
Pfizer; has provided expert testimony for Ashcraft & Gerel, LLP; has been supported
by the FP7 EU Project; and has received lecture fees from the Pediatric Society. R.
Selb has received research support from Fonds zur F€orderung der wissenschaftlichen
Forschung (Austrian Science Fund). V. Niederberger has received research support
from Fonds zur F€orderung der wissenschaftlichen Forschung (grant nos. SFB4613
and MCCA). R. Valenta has received research support and payment for the develop-
ment of educational presentations from Thermo Fisher and has received consultancy
fees from Thermo Fisher and Fresenius Medical Care. E. Wollmann declares that she
has no relevant conflicts of interest.REFERENCES
1. Dreborg S, Lee TH, Kay AB, Durham SR. Immunotherapy is allergen-specific: a
double-blind trial of mite or timothy extract in mite and grass dual-allergic
patients. Int Arch Allergy Immunol 2012;158:63-70.
2. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al.
Vaccination with genetically engineered allergens prevents progression of allergic
disease. Proc Natl Acad Sci U S A 2004;101:14677-82.
3. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of
recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunc-
tivitis. J Allergy Clin Immunol 2008;122:951-60.
4. Shamji MH, Durham SR. Mechanisms of immunotherapy to aeroallergens. Clin
Exp Allergy 2011;41:1235-46.
5. Lichtenstein LM, Ishizaka K, Norman PS, Sobotoka AK, Hill BM.
IgE antibody measurements in ragweed hay fever. J Clin Invest 1973;52:
472-82.
TABLE I. Subjects’ characteristics
Characteristic Control Asthma
P value
(2-tailed)
Sample size, n (male/female) 16 (8/8) 16 (10/6) .72
Age (y) 26.6 6 5.2 27.8 6 6.1 .58
BMI (kg/m2) 24.7 6 3.5 24.6 6 4.6 .96
FEV1 prebronchodilator
(% predicted)
96.3 6 12.1 81.3 6 15.1 .004
FEV1 postbronchodilator
(% predicted)
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Asthma Control
Questionnaire score
0.1 6 0.2 1.0 6 0.4 <.001
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ICS usage (%) 0.0 18.8 <.001
Combination ICS 1 LABA
usage (%)
0.0 43.8 <.001
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Physical activity, fitness, and vascular health
in patients with asthma
To the Editor:
Patients with asthma are at an increased risk of cardiovascular
disease (CVD),1 and increased systemic inflammation associated
with asthma may play a role. High levels of the proinflammatory
cytokines IL-6, C-reactive protein, and tumor necrosis factor-
alpha are elevated in asthma, and all are associated with increased
CVD risk.2,3 Reduced endothelial vasodilation is seen in early
stages of CVD development and is predictive of CVD.4 Patients
with asthma have reduced endothelial function and increased
arterial stiffness than do those without asthma.5,6 Systemic
inflammation impairs endothelial function7 and increases arterial
stiffness,8 but it is unknown whether there is a connection be-
tween systemic inflammation, vascular function, and arterial stiff-
ness in subjects with asthma. Importantly, patients with asthma
are usually more sedentary than their age-matched counterparts,9
and inactivity has been linked to increased inflammation, im-
paired vascular function, and increased CVD risk.10 Accordingly,
we evaluated parameters of vascular function and systemic
inflammation in patients with and without asthma matched for
physical activity and aerobic fitness. We hypothesized that those
with asthma would be associated with higher systemic inflamma-
tion, impaired endothelial function, and increased arterial stiff-
ness as compared with controls even when matched for physical
activity and aerobic fitness.
For complete methodology, see this article’s Methods section
in the Online Repository at www.jacionline.org. Briefly, patients
with asthma (18-45 years, n 5 16) with a body mass index of 30
kg/m2 or less were recruited and compared with age-, body mass
index-, physical activity-, and fitness-matched control subjects
(n5 16) without asthma. Asthma diagnosis was based on history
and 1) 12% or more and 200 mL improvement in FEV1 postbron-
chodilator, 2) a positive methacholine challenge (PC20 <_ 4 mg/
mL), or 3) 10% or more decrease in FEV1 after an exercise chal-
lenge. Controls demonstrated negative responses to all the 3 tests
described above. A cardiopulmonary exercise test was performed 2015 The Authors. Published by Elsevier, Inc. on behalf of the Academy of Allergy,
Asthma& Immunology. This is an open access article under the CCBY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/4.0/).to determine aerobic fitness (V
:
O2max). Physical activity was
quantified as the number of steps taken over 3 days by a physical
activity monitor. Vascular function was evaluated by flow-
mediated dilation (FMD) adjusted for shear stress, and arterial
stiffness was evaluated by the pulse wave velocity (PWV)
between the radial and the carotid arteries using applanation
tonometry. A blood sample was taken for analysis of systemic
inflammatory markers (ie, IL-6, C-reactive protein, and tumor
necrosis factor-alpha), fasting glucose, and cholesterol levels.
The Asthma Control Questionnaire indicated that patients with
asthma were within the ranges of controlled to partly controlled
asthma. There were no between-group differences in fraction of
exhaled nitric oxide, postbronchodilator FEV1, indices of blood
pressure, fasting glucose, lipid profiles, or systemic inflammatory
markers (see Table I). Although therewere no differences in endo-
thelial function (FMD) or microvascular function (velocity time
integral) between subjects with and without asthma, subjects
with asthma had significantly higher arterial stiffness than did
those without asthma (Fig 1). There was no relationship between
FMD and markers of systemic inflammation in asthma (see Fig
E1, A-C, in this article’s Online Repository at www.jacionline.
org); however, there was a strong positive correlation between
PWV and IL-6 in subjects with asthma, but no associations
were observed between PWV and tumor necrosis factor-alpha
or C-reactive protein (see Fig E1, E and F).
Whenmatched for age, bodymass index, physical activity, and
aerobic fitness, those with asthma and controls had similar
METHODS
Serum samples
Serum samples were residual samples from an immunotherapy trial
conducted with recombinant hypoallergenic Bet v 1 derivatives.E1 The study
began in November/December 2000, and the treatment course finished in
January/February 2001 before the birch pollen season, which lasted from
February to May 2001. The time point after 1 year described the follow-up
visit in October 2001. Eight up-dosing injections of fragment, trimer, or
placebowere administered (1, 2, 4, 8, 10, and 20mg of protein) in 1 or 2weekly
intervals as a preseasonal treatment. After reaching the maximal dose of 80mg
in the active groups, treatment was continued at 4 weekly intervals until the
beginning of the flowering season (Fig E1).
Administered immunotherapy preparations
Two recombinant Bet v 1 fragments representing amino acids 1 to 74 and
75 to 160 of the Bet v 1 allergen, respectively, were expressed in Escherichia
coli. These fragments showed almost no allergenic activity and a more than
100-fold reduced IgE-binding capacity and allergenic activity compared
with the complete allergen molecule.E2 The recombinant Bet v 1 trimer
protein consisted of 3 covalently linked copies of Bet v 1. Like the fragments,
it showed reduced allergenic activity.E3 Despite the lack of allergenic activity,
both types of derivatives induced after immunization robust production of IgG
antibodies in animals that also bound to the Bet v 1 allergen and inhibited
allergic patients’ IgE recognition of the allergen as well as allergen-induced
basophil degranulation.
Nasal provocation
Nasal provocation testing in the study was conducted with natural birch
pollen extract containing defined concentrations of Bet v 1. Provocation and
rhinomanometry measurements by active anterior rhinomanometry
(Allergopharma Rhinomanometer, Reinbek, Germany) were performed by a
trained investigator before treatment, after pollen seasons, and 1 year after the
study started. Baseline levels (nasal flow and resistance) were establishedwith
0.9% sodium chloride solution. Then, patients received intranasally (see
below) increasing doses of birch pollen extract solution (0.0064, 0.064, 0.64,
and 6.4 mg/mL), and 15 to 20 minutes postallergen application changes in
nasal parameters were determined. The evaluation was performed exactly as
described by Reisinger et al.E4
Measurement of allergen-specific IgE and IgG
ImmunoCAP measurements were done according to the manufacturer’s
instructions. ISAC chips were washed and 25 mL of the undiluted serum
samples was applied on the chip and incubated for 120 minutes at room
temperature. For allergen-specific IgG detection, samples were diluted 1:50 in
PBS 1 0.5% Tween 20. After washing, the chips were dried and incubated
with 25 mL of fluorescence-labeled anti-IgE detection antibody or anti-IgG
detection antibody, respectively, for 60 minutes at room temperature. Chips
were analyzed using the Laser Scan Confocal microarray reader (LuxScan
10K/A; Capital-Bio, Beijing, China). Results were evaluated using Phadia
Microarray Image Analysis software and reported in semi-quantitative ISAC
Standardized Units (ISU) with a cutoff of 0.3 ISU as recommended by the
manufacturer.
Calibration was performed with a commercial calibrator serum pool
reacting with a wide range of allergens with high and low IgE levels. For
these allergens ImmunoCAP measurements were performed. According to
manufacturer’s specifications, the ImmunoCAP-specific IgE calibrators can
be traced to the 2nd International Reference Preparation 75/502 of Human
Serum Immunoglobulin E from the World Health Organization. The same
reference sera are afterwards analyzed by using the microarray technology.
Resulting fluorescence values of the very same allergens tested by Immuno-
CAP are correlated with results of these samples acquired by ImmunoCAP
testing and correlation curves are then established. Calibration is performed in
every test run to maintain a consistent and reliable data generation.
This provides an indirect link of the ISU IgE antibody results obtained by
microarray testing with the World Health Organization International
Reference Preparation 75/502 IgE. Likewise, IgG calibration is achieved
with the help of reference sera, which are run in parallel for a broad panel of
allergens on IgG ImmunoCAPs and on the ISAC.E5
Statistical tests
Linear contrasts after ANOVA and correlations were calculated using
Statistica 10.0 (StatSoft) and SPSS 22.0 (IBM). Table E2 provides geometric
means for IgE and IgG measurements performed by ImmunoCAP and ISAC
for Bet v 1 and for IgE and IgG measurements done by ISAC for Aln g 1,
Cor a 1.0401, Mal d 1, and Pru p 1.
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FIG E1. Timeline of the SIT study. Blue arrows indicate the time points when blood samples were taken
(before treatment, after treatment, after season, after 1 year). Nasal provocation tests analyzed in this study
were performed before treatment (November/December 2000) and after season (May 2001).
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FIG E2. Courses of geometric means and 95% CIs of Aln g 1 (A and B) and Cor a 1 (C and D)-specific IgE and
IgG levels. *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from
the time point before treatment to after treatment, from after treatment to after season, and from after sea-
son to after 1 year.
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FIG E3. Course of geometric means and 95%CIs ofMal d 1 (A and B) or Pru p 1 (C andD)-specific IgE and IgG
levels. *P < .05 and **P < .01. Asterisks show the significance of changes within particular groups from the
time point before treatment to after treatment, from after treatment to after season, and from after season to
after 1 year.
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FIG E4. Association of alterations in Bet v 1–specific IgE levels determined by ImmunoCAP and nasal
allergen tolerance. Y-axes (positive range) indicate increased allergen-specific tolerance, wherein 1-point
increase indicates tolerance of a 10-fold higher allergen concentration and 1-point decrease indicates a
10-fold higher sensitivity. X-axes indicate the log fold changes of Bet v 1–specific IgE when comparing
prestudy levels (ie, before treatment; see Fig 1 and Fig E1) to levels measured after the pollen season
(ie, after season; see Fig 1 and Fig E1).
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TABLE E1. Characterization of birch pollen–allergic patients
Characteristic
Treatment group (N 5 65)
Placebo
(n 5 27)
Bet v 1 fragments
(n 5 17)
Bet v 1
trimer (n 5 21)
Sex (male/female) 33/32
Age (y), median (range) 37 (23-55) 35 (23-58) 36 (24-57)
Cumulative dose (mg), 0 165 165
median (range) (0) (4-245) (24-265)
Number of injections, 0 9 8
median (range) (0-0) (3-9) (7-10)
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2015
809.e6 LETTERS TO THE EDITOR
TABLE E2. Geometric means and 95% CIs of allergen-specific IgE and IgG levels determined for Bet v 1 (ImmunoCAP, ISAC), Aln g 1
(ISAC), Cor a 1.0401 (ISAC), Mal d 1 (ISAC), and Pru p 1 (ISAC)
Measurement
Geometric mean, 95% CI (low-high)
Group Before treatment After treatment After season After 1 y
For Bet v 1
Immuno CAP IgE Placebo (n 5 27) 11.1 (7.6-16.1) 12.2 (8.2-18.1) 24.7 (15.4-39.9) 19.6 (12.8-29.9)
Fragment (n 5 17) 18.4 (11.4-29.8) 29.1 (17.6-48.0) 42.5 (28.4-63.8) 25.8 (13.7-48.5)
Trimer (n 5 21) 20.3 (13.6-30.2) 34.2 (24.0-48.8) 43.2 (31.1-60.0) 30.0 (21.2-42.3)
Immuno CAP IgG Placebo (n 5 27) 2.9 (2.4-3.5) 3.0 (2.3-3.8) 3.4 (2.8-4.3) 3.4 (2.8-4.1)
Fragment (n 5 17) 2.9 (2.5-3.4) 6.0 (4.3-8.4) 4.7 (3.6-6.3) 3.8 (3.1-4.7)
Trimer (n 5 21) 3.3 (2.7-4.1) 10.3 (7.4-14.3) 7.9 (5.5-11.6) 5.2 (4.0-6.8)
ISAC IgE Placebo (n 5 27) 9.3 (6.5-13.5) 8.9 (6.2-12.7) 20.1 (14.3-28.5) 11.6 (8.0-16.8)
Fragment (n 5 17) 10.5 (6.2-17.8) 4.9 (2.7-9.0) 10.6 (5.5-20.3) 11.9 (7.6-18.5)
Trimer (n 5 21) 11.8 (7.8-18.1) 4.3 (2.7-6.6) 11.3 (7.3-17.4) 10.1 (6.7-15.3)
ISAC IgG Placebo (n 5 27) 1.1 (0.8-1.7) 0.9 (0.5-1.3) 0.9 (0.5-1.5) 0.9 (0.6-1.5)
Fragment (n 5 17) 1.1 (0.8-1.7) 3.1 (1.7-5.8) 2.9 (1.4-6.0) 2.2 (1.2-4.1)
Trimer (n 5 21) 1.2 (0.7-1.9) 5.1 (3.0-8.6) 4.1 (2.4-6.7) 1.5 (0.9-2.7)
Aln g 1
ISAC IgE Placebo (n 5 27) 1.4 (0.8-2.6) 1.4 (0.8-2.4) 4.1 (2.4-6.7) 2.2 (1.3-3.8)
Fragment (n 5 17) 1.9 (0.9-3.6) 1.0 (0.5-2.2) 2.4 (1.1-5.0) 2.7 (1.5-4.7)
Trimer (n 5 21) 2.3 (1.1-4.9) 1.3 (0.7-2.6) 3.0 (1.6-5.6) 3.0 (1.6-5.9)
ISAC IgG Placebo (n 5 27) 0.1 (0.1-0.3) 0.1 (0.1-0.2) 0.2 (0.1-0.3) 0.2 (0.1-0.4)
Fragment (n 5 17) 0.1 (0.1-0.3) 0.8 (0.3-2.3) 0.8 (0.3-2.3) 0.3 (0.1-0.9)
Trimer (n 5 21) 0.2 (0.1-0.5) 1.9 (0.9-4.1) 1.3 (0.6-2.6) 0.5 (0.2-1.1)
Cor a 1.0401
ISAC IgE Placebo (n 5 27) 1.8 (1.1-2.9) 1.7 (1.0-2.8) 3.9 (2.4-6.4) 2.1 (1.3-3.5)
Fragment (n 5 17) 2.3 (1.3-4.3) 2.1 (1.1-4.0) 3.5 (1.8-6.6) 2.9 (1.6-5.2)
Trimer (n 5 21) 1.7 (0.9-3.5) 1.5 (0.8-2.8) 3.3 (1.9-5.7) 2.5 (1.3-4.6)
ISAC IgG Placebo (n 5 27) 0.2 (0.1-0.4) 0.2 (0.1-0.3) 0.3 (0.5-0.1) 0.2 (0.4-0.1)
Fragment (n 5 17) 0.3 (0.1-0.7) 0.7 (0.3-1.7) 0.9 (0.3-2.6) 0.5 (0.2-1.5)
Trimer (n 5 21) 0.3 (0.1-0.6) 0.7 (0.3-1.8) 0.7 (0.3-1.8) 0.4 (0.2-0.9)
Mal d 1
ISAC IgE Placebo (n 5 27) 1.4 (0.9-2.3) 1.3 (0.8-2.2) 3.5 (2.0-5.9) 2.0 (1.3-3.3)
Fragment (n 5 17) 1.7 (0.8-3.8) 1.5 (0.7-3.1) 3.0 (1.5-5.8) 2.3 (1.2-4.4)
Trimer (n 5 21) 3.0 (1.8-4.9) 2.4 (1.3-4.3) 4.5 (2.7-7.6) 3.5 (2.1-5.8)
ISAC IgG Placebo (n 5 27) 0.2 (0.1-0.4) 0.2 (0.1-0.4) 0.2 (0.1-0.4) 0.3 (0.5-0.1)
Fragment (n 5 17) 0.3 (0.1-0.8) 0.5 (0.2-1.4) 0.8 (0.3-2.4) 0.5 (0.2-1.5)
Trimer (n 5 21) 0.3 (0.1-0.7) 0.5 (0.2-1.3) 0.6 (0.2-1.4) 0.3 (0.1-0.8)
Pru p 1
ISAC IgE Placebo (n 5 27) 1.2 (0.7-2.1) 1.1 (0.7-1.9) 3.4 (2.0-5.7) 1.8 (1.1-2.9)
Fragment (n 5 17) 1.1 (0.5-2.4) 0.9 (0.4-2.1) 1.9 (0.9-4.2) 1.4 (0.7-3.1)
Trimer (n 5 21) 1.4 (0.7-2.8) 1.3 (0.6-2.6) 2.6 (1.2-5.5) 1.6 (0.8-3.4)
ISAC IgG Placebo (n 5 27) 0.2 (0.1-0.3) 0.2 (0.1-0.3) 0.2 (0.1-0.4) 0.2 (0.1-0.4)
Fragment (n 5 17) 0.2 (0.1-0.5) 0.3 (0.1-0.8) 0.3 (0.1-1.0) 0.3 (0.1-1.0)
Trimer (n 5 21) 0.2 (0.1-0.5) 0.4 (0.2-1.2) 0.4 (0.2-1.2) 0.3 (0.1-0.8)
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